LAMIVUDINE/ZIDOVUDINE TABLETS CO-PACKAGED WITH NEVIRAPINE TABLETS

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

58 API Suppliers, 34 USDMF, 16 CEP/COS, 1 JDMF, 10 EU WC, 5 KDMF, 17 NDC API, 23 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

66 Drugs in Development

66 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

438 FDF Dossiers, 128 FDA Orange Book, 128 Europe, 21 Canada, 9 Australia, 118 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG, TABLET;ORAL - 150MG;200MG;300MG, TABLET;ORAL - 150MG, TABLET;ORAL - 300MG, TABLET;ORAL - 100MG;300MG;300MG, TABLET;ORAL - 300MG;300MG, TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 17 SPI Pharma, 6 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 25 BASF, 8 Beneo, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 2 Finar, 12 Gangwal Chemicals, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 19 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

73 Fillers, Diluents & Binders, 48 Coating Systems & Additives, 41 Direct Compression, 35 Disintegrants & Superdisintegrants, 30 Granulation, 30 Thickeners and Stabilizers, 27 Solubilizers, 27 Controlled & Modified Release, 25 Taste Masking, 21 Chewable & Orodispersible Aids, 19 Parenteral, 16 Topical, 15 Co-Processed Excipients, 14 Lubricants & Glidants, 12 Film Formers & Plasticizers, 8 Emulsifying Agents, 7 API Stability Enhancers, 6 Rheology Modifiers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 104 News #PharmaBuzz

GLOBAL SALES INFORMATION

28 US Medicaid Prescriptions, 33 Regulatory FDF Prices, 35 Annual Reports

MARKET PLACE

15 APIs, 10 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 6 US Exclusivities, 44 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 4 USP, 7 Others

ANALYTICAL

1 BioAnalytical Methods, 1 Analytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 211284 / DOSAGE - TABLET;ORAL - 300MG;300MG

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
LAMIVUDINE(UNII: 2T8Q726O95) (LAMIVUDINE - UNII:2T8Q726O95)	LAMIVUDINE	300mg
TENOFOVIR DISOPROXIL FUMARATE(UNII: OTT9J7900I) (TENOFOVIR ANHYDROUS - UNII:W4HFE001U5)	TENOFOVIR DISOPROXIL FUMARATE	300mg

Inactive Ingredients

Ingredient Name	CELLTRION, INC.
CROSCARMELLOSE SODIUM(M28OL1HH48)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
LACTOSE MONOHYDRATE(EWQ57Q8I5X)
MAGNESIUM STEARATE(70097M6I30)
POLYETHYLENE GLYCOL, UNSPECIFIED(3WJQ0SDW1A)
POWDERED CELLULOSE(SMD1X3XO9M)
SILICON DIOXIDE(ETJ7Z6XBU4)
TITANIUM DIOXIDE(15FIX9V2JP)

Drug Product Composition: LAMIVUDINE/ZIDOVUDINE TABLETS CO-PACKAGED WITH NEVIRAPINE TABLETS